Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma

Head and Neck

Volumn 38, Issue , 2016, Pages E853-E858

  Leung, Alan S ^a,b   Rath, Tanya J ^a   Hughes, Marion A ^a   Kim, Seungwon ^a   Branstetter, Barton F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

fluorodeoxyglucose (FDG); head and neck squamous cell carcinoma; positron emission tomography (PET) CT; posttreatment; timing

Indexed keywords

FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18;

ADULT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; AGED; DIAGNOSTIC IMAGING; HEAD AND NECK TUMOR; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TIME FACTOR; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; YOUNG ADULT;

EID: 84937134573     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24112     Document Type: Conference Paper

References (19)

1. NCCN clinical practice guidelines in oncology: head and neck cancers. [National Comprehensive Cancer Network Web Site]. February 1, 2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/head-and-neck.pdf. Accessed September 22, 2013.
2. Bourhis J, Sire C, Graff P, et al., Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 2 randomized trial. Lancet Oncol 2012; 13: 145-153.
3. Beswick DM, Gooding WE, Johnson JT, Branstetter BF IV,. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope 2012; 122: 1512-1517.
4. Mukherji SK, Mancuso AA, Kotzur IM, et al., Radiologic appearance of the irradiated larynx. Part II. Primary site response. Radiology 1994; 193: 149-154.
5. Kresnik E, Mikosch P, Gallowitsch HJ, et al., Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 2001; 28: 816-821.
6. Branstetter BF IV, Blodgett TM, Zimmer LA, et al., Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235: 580-586.
7. Abgral R, Querellou S, Potard G, et al., Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009; 50: 24-29.
8. Rabalais AG, Walvekar R, Nuss D, et al., Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope 2009; 119: 1120-1124.
9. Ryan WR, Fee WE Jr, Le QT, Pinto HA,. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650.
10. Greven KM, Williams DW III, McGuirt WF Sr, et al., Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-946.
11. Andrade RS, Heron DE, Degirmenci B, et al., Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1315-1322.
12. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H,. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 2010; 37: 1318-1327.
13. Gupta T, Master Z, Kannan S, et al., Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011; 38: 2083-2095.
14. Moeller BJ, Rana V, Cannon BA, et al., Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009; 27: 2509-2515.
15. McDermott M, Hughes M, Rath T, et al., Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol 2013; 34: 1632-1636.
16. Ho AS, Tsao GJ, Chen FW, et al., Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013; 119: 1349-1356.
17. Ong SC, Schöder H, Lee NY, et al., Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540.
18. Zhang I, Branstetter BF IV, Beswick DM, Maxwell JH, Gooding WE, Ferris RL,. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2011; 137: 1106-1111.
19. Isles MG, McConkey C, Mehanna HM,. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33: 210-222.